{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:22:02Z","timestamp":1765887722969,"version":"3.40.4"},"reference-count":20,"publisher":"S. Karger AG","issue":"7-8","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Glioblastoma (GB) is the most common malignant primary central nervous system tumor in adults. Standard-of-care therapy includes surgical resection, radiotherapy and temozolomide, but nearly all patients experience disease progression. The purpose of this study was to describe 2 cohorts of patients with recurrent GB submitted to second-line treatment with procarbazine\/lomustine\/vincristine (PCV) or bevacizumab\/irinotecan (BI). &lt;b&gt;&lt;i&gt;Material and Methods:&lt;\/i&gt;&lt;\/b&gt; Retrospective analysis of GB patients treated in our center with PCV or BI, after progression with temozolomide, between 2004 and 2012. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Among 60 patients, 41 were treated with BI and 19 with PCV. According to the Macdonald criteria, the overall response rate in the BI group was 66% (n = 27) while it was 11% (n = 2) in the PCV group. The median progression-free survival was 5 and 3 months in the BI and PCV group, respectively. The median overall survival (OS) since second-line chemotherapy was 9 months in the BI group and 5 months in the PCV group. The latter group had a worse toxicity profile (grade 3-4: 52.6% vs. 22.0%; grade 1-2: 89.5% vs. 68.3%). &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; The BI cohort had higher response rates, almost twice the OS and a lower degree of toxicity in contrast to the PCV group. The small number of patients and historical cohorts limits these comparisons.<\/jats:p>","DOI":"10.1159\/000431236","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T22:35:53Z","timestamp":1434580553000},"page":"348-354","source":"Crossref","is-referenced-by-count":20,"title":["Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study"],"prefix":"10.1159","volume":"38","author":[{"given":"Bruno F.","family":"Carvalho","sequence":"first","affiliation":[]},{"given":"Ana C.","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Daniela S.","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Lu\u00edsa V.","family":"Sampaio","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Claudia","family":"Caeiro","sequence":"additional","affiliation":[]},{"given":"L\u00edgia","family":"Os\u00f3rio","sequence":"additional","affiliation":[]},{"given":"L\u00edgia","family":"Castro","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Linhares","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Damasceno","sequence":"additional","affiliation":[]},{"given":"Rui C.","family":"Vaz","sequence":"additional","affiliation":[]}],"member":"127","published-online":{"date-parts":[[2015,6,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3747\/co.v18i3.755"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00177478"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/BF01051050"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-6090-9_23"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2440"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8721"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A2397"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3541"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181bc0184"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.10.038"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000304121.57857.38"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.1932"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3055"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2309"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-252"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2011.12.028"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-008-9718-y"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70314-6"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-008-9599-0"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.01.027"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/431236","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/431236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:12:03Z","timestamp":1745431923000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000431236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":20,"journal-issue":{"issue":"7-8","published-online":{"date-parts":[[2015,8,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000431236","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"type":"print","value":"2296-5270"},{"type":"electronic","value":"2296-5262"}],"subject":[],"published":{"date-parts":[[2015]]}}}